Sandra Horning, MD
The European Commission (EC) has approved alectinib (Alecensa) for the frontline treatment of patients with ALK
-positive metastatic non–small cell lung cancer (NSCLC), according to Roche, the manufacturer of the second-generation ALK inhibitor.
-positive NSCLC in the United States, Japan, and Turkey.
European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer. Roche. Available at: https://www.roche.com/media/store/releases/med-cor-2017-12-21.htm. Accessed December 22, 2017.
... to read the full story